ROGDI Inhibitors
Chemical inhibitors of ROGDI can exert their functional inhibitory effects through intervention in critical cellular pathways that are essential for the normal functioning of the protein. Alsterpaullone, olomoucine, roscovitine, NU2058, NU6027, purvalanol A, indirubin-3'-monoxime, flavopiridol, dinaciclib, SNS-032, AZD5438, and R-roscovitine are all inhibitors that primarily target cyclin-dependent kinases (CDKs), which are pivotal in cell cycle progression and DNA damage response, processes in which ROGDI is known to be involved. By inhibiting CDKs, these chemicals can disrupt the progression of the cell cycle, thereby impeding ROGDI's role in the regulation and maintenance of DNA integrity during cell cycle checkpoints. The interruption of normal cell cycle progression by these CDK inhibitors can therefore result in an indirect but functional inhibition of ROGDI by preventing it from participating in its normal cellular roles.
Moreover, some of these inhibitors, such as NU6027, not only target CDKs but also modulate DNA repair mechanisms by enhancing homologous recombination repair, which in turn can alter the functional dynamics of ROGDI in DNA repair pathway selection. Inhibitors like indirubin-3'-monoxime and flavopiridol have broader kinase target profiles that include GSK-3β, which is involved in a variety of cellular processes including cell cycle control. By broadly disrupting kinase activity, these inhibitors can create a cellular environment that is inhospitable to ROGDI's normal function, leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). Since ROGDI is implicated in DNA damage response and CDKs are integral to cell cycle progression, alsterpaullone inhibition of CDKs can lead to a halt in cell cycle progression that ROGDI is involved in, leading to functional inhibition of ROGDI through cell cycle arrest. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor, which by inhibiting CDKs, can indirectly inhibit ROGDI by disrupting the cell cycle and DNA damage response processes, both of which are cellular pathways where ROGDI has a role. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine serves as an inhibitor of CDKs, and by inhibiting these kinases, it can interfere with cell cycle control and DNA repair mechanisms, thus indirectly inhibiting ROGDI's functional role within these pathways. | ||||||
NU2058 | 161058-83-9 | sc-202744 sc-202744A | 5 mg 25 mg | $66.00 $321.00 | 2 | |
NU2058 is a guanine-based CDK inhibitor that targets CDK2, which is crucial for cell cycle progression, hence indirectly inhibiting ROGDI’s associated functions in cell cycle control. | ||||||
NU6027 | 220036-08-8 | sc-215591 | 10 mg | $156.00 | 1 | |
NU6027 is a potent inhibitor of CDKs and enhances homologous recombination repair, thereby potentially inhibiting ROGDI's role in DNA damage responses by altering the balance of DNA repair pathway choice. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A, a potent CDK inhibitor, can interrupt the cell cycle process, indirectly inhibiting the functional role of ROGDI within the cell cycle regulation and DNA damage response pathway. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is a known inhibitor of CDKs and GSK-3β. Inhibition of these kinases can indirectly disrupt cellular processes such as cell cycle progression and DNA repair, in which ROGDI is implicated. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs, potentially leading to disruption of the cell cycle and DNA damage pathways, indirectly inhibiting the functional role of ROGDI within these processes. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor that can interfere with cell cycle progression. By inhibiting CDKs, dinaciclib can indirectly inhibit ROGDI's role in the DNA damage response. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a potent and selective inhibitor of CDKs involved in regulation of transcription and cell cycle. By disrupting these processes, SNS-032 can indirectly inhibit ROGDI's function in cell cycle and DNA repair pathways. | ||||||